Navigation Links
InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
Date:5/20/2009

InVitria’s BioProcess Theater presentation, “New Strategies for Optimizing CHO Performance,” to feature new supplement for CHO cell culture optimization called ZAP-CHO during BIO 2009 International Convention in Atlanta, GA. 

Fort Collins, CO May 19, 2009 / b3c newswire / – InVitria’s Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture, at 3:30 pm on Wednesday, May 20, 2009 as part of BioProcess International’s BioProcess Theatre, a venue employed to facilitate the sharing of advances and discoveries in the biopharmaceutical sector.  

ZAP-CHO, a new product from InVitria, enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media.

“Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well,” said Dr. Pettit. “InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency.”

InVitria’s other leading cell culture media supplements will also be part of the BIO Process Product Zone exhibition in Booth #5120 within the BIO 2009 International Convention from May 19-21.  These supplements include:
* Albumin-DX—whether you have problems with non-specific binding, biomarker stability, consistency or regulatory requirements, Albumin-DX was designed to answer the most difficult assay challenges.
* Cellastim—Cellastim outperforms plasma-derived albumin, bovine serum albumin and other sources of recombinant albumin.
* Lacromin—Lacromin is a CHO growth-factor that outperforms insulin and IGF-1.


About InVitria - www.InVitria.com

InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

Contact
Erik H. Vogel
InVitria
Marketing Manager
Phone: 1-800-916-8311
info@InVitria.com
www.InVitria.com


'/>"/>
b3c newswire

Related biology news :

1. InVitria Announces Launch of Recombinant Albumin for Diagnostics
2. Unveiling the structure of microcrystals
3. EC unveils new EU maritime policy
4. Scientists unveil structure of molecular target of many drugs
5. Tumor genome analysis unveils new insights into lung cancer
6. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
7. Research unveils new hope for deadly childhood disease
8. LTER unveils a new decadal science plan
9. Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition
10. Unveiling the underwater ways of the white shark
11. Washington University unveils draft sequence of corn genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... 2017 Summary This report provides all ... partnering interests and activities since 2010. ... Read the full report: ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ...
(Date:3/2/2017)... MELBOURNE, Australia , March 2, 2017 ... Therapeutics Ltd (ASX: CYP), has signed an agreement ... researchers from the Monash Biomedicine Discovery Institute and Department ... , to conduct a further preclinical study to support ... the treatment of asthma.  Asthma is ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and ... ... to 16 March, Materna will present its complete end-to-end passenger ... is a real benefit for passengers. To accelerate the whole ... touch point solutions to take passengers through the complete integrated ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... , March 24, 2017 MiMedx Group, Inc. ... utilizing human placental tissue allografts and patent-protected processes to ... sectors of healthcare, announced today  that it will present ... York , NY.  Parker H. "Pete" Petit, Chairman ... Officer, Christopher M. Cashman , EVP and Chief ...
(Date:3/24/2017)... WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ ... medical dermatology and aesthetics company, today announced that ... Financial Officer, effective March 24.   Peterson, who ... will succeed John Smither , who is retiring ... serve Sienna in an advisory capacity. Peterson joins Sienna ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
Breaking Biology Technology: